Invomit

Invomit

ondansetron

Manufacturer:

Interbat
Concise Prescribing Info
Contents
Ondansetron HCl dihydrate
Indications/Uses
Management of nausea & vomiting induced by cytotoxic chemotherapy & radiotherapy. Prevention & treatment of post-op nausea & vomiting.
Dosage/Direction for Use
Adult Highly emetogenic chemotherapy Initially 8 mg slow IV or 15 min infusion immediately before chemotherapy, followed by 1 mg/hr for up to 24 hr or a further 2 doses of 8 mg by slow IV or 15 min infusion 4 hr apart. Either regimen is then followed by 8 mg orally every 12 hr for 5 days. Less emetogenic chemotherapy 8 mg by slow IV or 15 min infusion immediately after chemotherapy or 8 mg orally 1-2 hr before chemotherapy, followed by 8 mg orally every 12 hr for 5 days. Radiotherapy-induced nausea & vomiting 8 mg orally 12 hrly 1-2 hrs before radiotherapy. Childn 5 mg/m2 IV for 15 min, immediately before chemotherapy followed by 4 mg orally 12 hrly for 5 days. Hepatic impairment Not to exceed 8 mg.
Administration
May be taken with or without food.
Special Precautions
Pregnancy & lactation.
Adverse Reactions
Constipation, headache, sedation, warm sensation in the head & epigastrum; occasional transient, asymptomatic increases in aminotransferases. Rarely, hypersensitivity reactions.
ATC Classification
A04AA01 - ondansetron ; Belongs to the class of serotonin (5HT3) antagonists. Used for the prevention of nausea and vomiting.
Presentation/Packing
Form
Invomit inj 8 mg/4 mL
Packing/Price
(amp) 5 × 1's (Rp190,000.00/boks)
Form
Invomit inj 4 mg/2 mL
Packing/Price
5 × 1's (Rp100,000.00/boks)
Form
Invomit film-coated tab 4 mg
Packing/Price
3 × 6's (Rp225,000.00/boks)
Form
Invomit film-coated tab 8 mg
Packing/Price
3 × 6's (Rp342,000.00/boks)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in